Fountain Healthcare Partners is an Irish-based life science venture capital fund. Fountain is exclusively focused on the life science
Business Model:
Revenue: $11.4M
Employees: 11-50
Address: Guild Street, IFSC
City: Dublin
State: county dublin
Zip:
Country: IE
Fountain Healthcare Partners is an Irish based life science venture capital fund. Fountain is exclusively focused on the life science sector. Specific areas of interest to them are: specialty pharma, medical devices, biotechnology and diagnostics. They will deploy the majority of their capital in Europe with a strong focus on Ireland.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
1/2021 | Neurent Medical | Series B | 0 |
7/2012 | Neuravi | Series A | 6.4M |
4/2018 | MMI | Series A | 24.8M |
5/2018 | Neurent Medical | Venture Round | 10.8M |
9/2012 | Mainstay Medical | Series B | 20M |
6/2015 | Neuravi | Series B | 21.5M |
9/2013 | Civitas Therapeutics | Series B | 0 |
7/2022 | MMI | Series B | 0 |
10/2009 | Amarin | Post-IPO Equity | 70M |
10/2018 | Velicept Therapeutics | Series B | 15M |
2/2018 | Syndesi Therapeutics | Series A | 21.3M |
6/2009 | Opsona | Series B | 4.6M |
9/2016 | Inflazome | Series A | 17M |
9/2016 | Chrono Therapeutics | Series B | 47.6M |
9/2020 | Syndesi Therapeutics | Series A | 7M |
2/2018 | Mainstay Medical | Post-IPO Equity | 37.5M |
9/2015 | Neuromod Devices | Series A | 7.7M |
10/2020 | Neuromod Devices | Series B | 12.4M |
10/2013 | Opsona | Series C | 0 |
4/2013 | Opsona | Series C | 0 |
4/2023 | Neuromod Devices | Series B | 0 |
5/2022 | Vivasure Medical | Series D | 0 |
3/2021 | XyloCor Therapeutics | Series A | 0 |
2/2021 | Mainstay Medical | Private Equity Round | 0 |
10/2010 | Cappella Medical Devices | Series D | 14.6M |
7/2009 | Cappella Medical Devices | Series C | 17.3M |
6/2022 | Ermium Therapeutics | Series A | 0 |
10/2020 | Priothera | Series A | 0 |
8/2018 | KaNDy Therapeutics | Series C | 32.6M |
8/2014 | Civitas Therapeutics | Series C | 0 |
1/2017 | NeRRe Therapeutics | Series B | 28.6M |
5/2023 | Dualyx | Series A | 0 |
2/2009 | Vivasure Medical | Series A | 11.6M |
9/2021 | Calypso Biotech | Series A | 0 |
11/2009 | Genable Technologies Ltd. | Series B | 7.5M |
2/2020 | Inotrem | Series B | 5.5M |
9/2019 | Neuromod Devices | Series A | 8.7M |
6/2014 | Chrono Therapeutics | Series A | 32M |
5/2013 | Trino Therapeutics | Series A | 11.6M |
9/2016 | Vivasure Medical | Series C | 18.3M |
7/2021 | NeRRe Therapeutics | Series B | 0 |
8/2009 | Palyon Medical | Series A | 24M |
5/2023 | Dualyx | Series A | 0 |
4/2023 | Neuromod Devices | Series B | 0 |
7/2022 | MMI | Series B | 0 |
6/2022 | Ermium Therapeutics | Series A | 0 |
5/2022 | Vivasure Medical | Series D | 0 |
9/2021 | Calypso Biotech | Series A | 0 |
7/2021 | NeRRe Therapeutics | Series B | 0 |
3/2021 | XyloCor Therapeutics | Series A | 0 |
2/2021 | Mainstay Medical | Private Equity Round | 0 |
1/2021 | Neurent Medical | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|